What's New in SCLC? A Review

A few years ago the answer to the question in the title of this review would have been, “unfortunately not much” or even “nothing”, likely eliciting knowing nods of agreement from oncologists. For the last 3 decades, SCLC has been notorious for its lack of progress, as drug after drug, over 60 of th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neoplasia (New York, N.Y.) Jg. 19; H. 10; S. 842 - 847
Hauptverfasser:	Oronsky, Bryan, Reid, Tony R., Oronsky, Arnold, Carter, Corey A.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Elsevier Inc 01.10.2017 Elsevier Limited Neoplasia Press Elsevier
Schlagworte:	Clinical trials DNA-directed RNA polymerase Drug development Epidemiology Epidermal growth factor receptors Humans Immune checkpoint Immunotherapy Lung Neoplasms - diagnosis Lung Neoplasms - epidemiology Lung Neoplasms - etiology Lung Neoplasms - therapy Molecular Targeted Therapy Neoplasm Staging Non-small cell lung carcinoma Poly(ADP-ribose) polymerase Prevalence Prognosis Review article Reviews RNA polymerase Small cell lung carcinoma Small Cell Lung Carcinoma - diagnosis Small Cell Lung Carcinoma - epidemiology Small Cell Lung Carcinoma - etiology Small Cell Lung Carcinoma - therapy TOR protein Treatment Outcome Vascular endothelial growth factor
ISSN:	1476-5586, 1522-8002, 1476-5586, 1522-8002
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!